Cerus Corporation (NasdaqGM:CERS) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Cerus Corporation to reach your target.
Hmm, we can't give any reliable projection for Cerus Corporation's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| CERS Price (Cerus Corporation stock price per share) |
$2.65 | |
| PE Ratio versus Sector | 100% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 100% lower than other Medical Devices stocks | |
| Cash Yield | -9.57% | |
| Free Cash Flow Jitter | 19% |
In the six months to 2026-11-10, no insider bought shares, and 5 insiders sold in 8 trades, about $841 thousand.
The six months before that had 0 buys and 14 sales.
Open-market buys and sells reported by Cerus Corporation's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-17 | Jensen Chrystal (Chief Legal Officer) | Sell | 30,000 | $2.98 |
| 2026-07-16 | Jayaraman Vivek K (Chief Executive Officer) | Sell | 16,666 | $3.16 |
| 2026-06-30 | Green Kevin Dennis (Chief Financial Officer) | Sell | 33,676 | $2.94 |
| 2026-06-30 | Jensen Chrystal (Chief Legal Officer) | Sell | 24,329 | $2.94 |
| 2026-06-30 | Greenman William Mariner (President and CEO) | Sell | 101,919 | $2.94 |
| 2026-06-30 | Jayaraman Vivek K (Chief Operating Officer) | Sell | 42,359 | $2.94 |
| 2026-06-09 | BJERKHOLT ERIC | Sell | 20,454 | $2.60 |
| 2026-05-29 | Jayaraman Vivek K (Chief Operating Officer) | Sell | 16,667 | $3.00 |
| 2026-05-01 | Jayaraman Vivek K (Chief Operating Officer) | Sell | 16,667 | $3.00 |
| 2026-03-12 | Jayaraman Vivek K (Chief Operating Officer) | Sell | 165,200 | $1.66 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 17,717,716 shares shorted. With 195,348,160 shares available for purchase and an average trading volume over the past 10 trading days of 1,222,940, it would take at least 14.5 days for all of the short holders to cover their shorts.
What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2009 | 1020214 | -14.7 |
| 2010 | 1020214 | -15.2 |
| 2011 | 1020214 | -16.3 |
| 2012 | 1020214 | -14.4 |
| 2013 | 1020214 | -27.4 |
| 2014 | 1020214 | -40.8 |
| 2015 | 1020214 | -51.9 |
| 2016 | 1020214 | -54.4 |
| 2017 | 1020214 | -53.1 |
| 2018 | 1020214 | -32.2 |
| 2019 | 1020214 | -67.8 |
| 2020 | 1020214 | -44.3 |
| 2021 | 1020214 | -36.5 |
| 2022 | 1020214 | -28.5 |
| 2023 | 1020214 | -46.8 |
| 2024 | 1020214 | 9.0 |
| 2025 | 1020214 | 2.0 |
Download the yearly data as CSV.
Free cash flow was positive in 2 out of 17 reported years for Cerus Corporation, using only its current SEC filer.
Free cash flow is fairly steady from year to year, with a variability measure of 19%.
We do not estimate a fair value for Cerus Corporation while its free cash flow growth is not positive, so there is no value comparison here.
Dividends are not in our data for Cerus Corporation.
These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.
Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 100% below the average for stocks in the Medical Devices industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
Every fiscal year on this page is reported by one SEC filer, CIK 1020214.
Each figure on this page comes from that filer.
Advertisement supports free stock analysis content.
Does Cerus Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to CERS: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data
What Does a Trump Administration Mean for the Stock Market?
What is the myRA Retirement Savings Account?
What Happened to the Stock Market Today?